ArticleIndian journal of ophthalmology2021
Endogenous fungal endophthalmitis following intensive corticosteroid therapy in severe COVID-19 disease.
Article in Indian journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Understanding the science of fungal endophthalmitis - AIOS 2021 Sengamedu Srinivas Badrinath Endowment Lecture.Indian journal of ophthalmology · 2022Trial
- Rhino-Orbital-Cerebral Mucormycosis With Bilateral EndogenousCase reports in ophthalmological medicine · 2026Article
- Post-coronavirus disease bilateral endogenous fungal endophthalmitis with full visual acuity recovery: a case report.Journal of medical case reports · 2025Article
- Review
- Endophthalmitis: a bibliometric study and visualization analysis from 1993 to 2023.Frontiers in cellular and infection microbiology · 2024Article
- Sudden vision loss heralding COVID-19-associated aspergillosis. Report of 2 cases.American journal of ophthalmology case reports · 2023Article
- The Role of Adjuvant Systemic and Intravitreal Corticosteroids in Fungal Endophthalmitis Treatment.Journal of fungi (Basel, Switzerland) · 2023Review
- Endogenous endophthalmitis in post-COVID-19 patients: a case report.Annals of medicine and surgery (2012) · 2023Article
- Microbiology Profile of COVID-19-Associated Rhino-Orbital Mucormycosis Pathogens in South India.The American journal of tropical medicine and hygiene · 2023Article
- Article
- Fundus findings in patients admitted with post COVID-19 sepsis in an intensive care unit.Indian journal of ophthalmology · 2022Observational
- Commentary: Fulminant fungal endogenous endophthalmitis following COVID-19.Indian journal of ophthalmology · 2022Article
- Effect of COVID-19 Lockdowns on Eye Emergency Department, Increasing Prevalence of Uveitis and Optic Neuritis in the COVID-19 Era.Healthcare (Basel, Switzerland) · 2022Article
- Fulminant fungal endogenous endophthalmitis following SARS-CoV-2 infection: A case report.Indian journal of ophthalmology · 2022Article
- Analysis of COVID-19 publications in theIndian journal of ophthalmology · 2022Article
- Endogenous fungal endophthalmitis in COVID-19 patients: An unexplored possibility.Indian journal of ophthalmology · 2022Article
- The Diagnosis and Treatment of Fungal Endophthalmitis: An Update.Diagnostics (Basel, Switzerland) · 2022Review
- Commentary: Fungal endophthalmitis - Newer insights into the diagnosis and management.Indian journal of ophthalmology · 2022Article
- Unilateral Endogenous Bacterial Endophthalmitis Post-Coronavirus Disease-19 in an Healthy Asian Indian Male.Beyoglu eye journal · 2022Article
- Commentary: A case of endogenous candida endophthalmitis with incidental cytomegalovirus infection and optic neuropathy in a patient recovered from severe COVID-19.Indian journal of ophthalmology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report endogenous fungal endophthalmitis, postrecovery from severe COVID-19 infection in otherwise immunocompetent individuals, treated with prolonged systemic steroids. Methods: Retrospective chart review of cases with confirmed and presumed fungal endogenous endophthalmitis, following severe COVID-19 disease, treated at two tertiary care referral eye institutes in North India. Results: Seven eyes of five cases of endogenous fungal endophthalmitis were studied. All cases had been hospitalized for severe COVID-19 pneumonia and had received systemic steroid therapy for an average duration of 42 ± 25.1 days (range 18-80 days). All the cases initially complained of floaters with blurred vision after an average of 6 days (range 1-14 days) following discharge from hospital. They had all been misdiagnosed as noninfectious uveitis by their primary ophthalmologists. All eyes underwent pars plana vitrectomy (PPV) with intravitreal antifungal therapy. Five of the seven eyes grew fungus as the causative organism (Candida sp. in four eyes, Aspergillus sp. in one eye). Postoperatively, all eyes showed control of the infection with a marked reduction in vitreous exudates and improvement in vision. Conclusion: Floaters and blurred vision developed in patients after they recovered from severe COVID-19 infection. They had received prolonged corticosteroid treatment for COVID-19 as well as for suspected noninfectious uveitis. We diagnosed and treated them for endogenous fungal endophthalmitis. All eyes showed anatomical and functional improvement after PPV with antifungal therapy. It is important for ophthalmologists and physicians to be aware of this as prompt treatment could control the infection and salvage vision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.